Clinical Trials Logo

Thyroid Cancer, Papillary clinical trials

View clinical trials related to Thyroid Cancer, Papillary.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02152995 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Start date: August 14, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.

NCT ID: NCT01723202 Active, not recruiting - Clinical trials for Papillary Thyroid Cancer

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Start date: November 7, 2012
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether dabrafenib is more effective when given with or without trametinib in treating thyroid cancer

NCT ID: NCT00381641 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Start date: August 8, 2006
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.